CW Advisors LLC Increases Stake in Cencora, Inc. $COR

CW Advisors LLC raised its position in shares of Cencora, Inc. (NYSE:COR) by 181.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,116 shares of the company’s stock after purchasing an additional 17,466 shares during the quarter. CW Advisors LLC’s holdings in Cencora were worth $8,131,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in COR. Norges Bank bought a new stake in shares of Cencora during the second quarter valued at approximately $695,215,000. Artisan Partners Limited Partnership purchased a new stake in Cencora during the 2nd quarter valued at $411,888,000. Invesco Ltd. increased its holdings in shares of Cencora by 42.1% in the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after purchasing an additional 1,125,661 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of Cencora by 4,459.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock worth $277,321,000 after purchasing an additional 975,362 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.6%

COR opened at $337.43 on Friday. The firm’s 50 day simple moving average is $339.40 and its two-hundred day simple moving average is $309.16. The company has a market capitalization of $65.42 billion, a PE ratio of 42.44, a PEG ratio of 1.59 and a beta of 0.63. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 46,640 shares of company stock worth $14,099,338. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on COR. Wells Fargo & Company increased their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. UBS Group boosted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.